Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society Annual Meeting
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
SAGA Metals Achieves 100% Drilling Success in 2025-Reports Final Assays from Trapper South at Radar Critical Minerals Project in Labrador
Domestic Metals Initiates Geophysical Program at the Smart Creek Project and announces non-brokered Private Placement
Nextech3D.ai Expands Krafty Lab Enterprise Engagement Platform with F-35 Flight Simulation Experiences Through The Squadron Partnership
